INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $144,566 | +35.3% | 146,000 | +33.9% | 0.00% | – |
| Q4 2022 | $106,823 | +1.7% | 109,000 | 0.0% | 0.00% | – |
| Q3 2022 | $105,000 | +72.1% | 109,000 | +70.3% | 0.00% | – |
| Q2 2022 | $61,000 | +32.6% | 64,000 | +28.0% | 0.00% | – |
| Q1 2022 | $46,000 | -2.1% | 50,000 | 0.0% | 0.00% | – |
| Q4 2021 | $47,000 | +4.4% | 50,000 | 0.0% | 0.00% | – |
| Q3 2021 | $45,000 | -50.0% | 50,000 | -50.0% | 0.00% | – |
| Q2 2021 | $90,000 | +11.1% | 100,000 | 0.0% | 0.00% | – |
| Q1 2021 | $81,000 | +44.6% | 100,000 | +38.9% | 0.00% | – |
| Q4 2020 | $56,000 | -59.1% | 72,000 | -57.6% | 0.00% | – |
| Q3 2020 | $137,000 | -9.3% | 170,000 | -15.0% | 0.00% | – |
| Q2 2020 | $151,000 | -32.6% | 200,000 | -28.6% | 0.00% | -100.0% |
| Q1 2020 | $224,000 | -20.6% | 280,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $282,000 | -11.3% | 280,000 | -24.3% | 0.00% | 0.0% |
| Q3 2019 | $318,000 | -3.6% | 370,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $330,000 | -9.8% | 370,000 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $366,000 | +18.4% | 370,000 | +10.4% | 0.00% | 0.0% |
| Q4 2018 | $309,000 | -8.8% | 335,000 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $339,000 | – | 335,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|